Wolfe reiterates Outperform on Natera after favorable jury decision

Wolfe Research says a jury has found patents held by Natera (NTRA) to be valid and that CareDx (CDNA) infringes one of the two patents included in the dispute. The jury ruling fortifies conviction in the strength of Natera’s IP portfolio, further boosts confidence in management execution, and “could have balance sheet and P&L benefits,” says the analyst, who is told that the damages hearing is likely to conclude next week. Wolfe reiterates an Outperform rating on Natera shares with a $70 price target.